Edition:
United States

Panion & BF Biotech Inc (1760.TWO)

1760.TWO on Gre Tai Securities Market of Chinese Taipei

130.49TWD
22 Jul 2016
Change (% chg)

NT$-0.16 (-0.12%)
Prev Close
NT$129.99
Open
NT$130.00
Day's High
NT$134.72
Day's Low
NT$129.00
Volume
74,535
Avg. Vol
97,678
52-wk High
NT$185.00
52-wk Low
NT$67.16

Latest Key Developments (Source: Significant Developments)

Panion & BF Biotech to pay 2015 cash dividend on Aug. 19
Thursday, 14 Jul 2016 06:51am EDT 

Panion & BF Biotech <1760.TWO>: Says it will pay cash dividend of T$44,999,860 in total for 2015 . Says it will pay stock dividend of T$56,249,830 in total . Ex-dividend and ex-right date July 29 . Last date before book closure Aug. 1 with book closure period from Aug. 2 to Aug. 6 . Record date Aug. 6 .Cash dividend payment date Aug. 19.  Full Article

Panion & BF Biotech says Lin Jyh Ming to no longer serve as chairman
Friday, 3 Jun 2016 04:48am EDT 

Panion & BF Biotech <1760.TWO>:Says Lin Jyh Ming will no longer serve as chairman of the board.  Full Article

Panion & BF Biotech announces 2015 dividend payment
Thursday, 21 Apr 2016 05:48am EDT 

Panion & BF Biotech Inc:To use undistributed profit to pay cash dividends of T$0.80 per share to shareholders for 2015.To pay cash dividend of T$44,999,860 in total.To use undistributed profit to distribute stock dividend worth T$0.30 for every one share.To use additional paid-in capital to distribute stock dividend worth T$0.70 for every one share.To distribute stock dividend of 5,624,983 shares in total.  Full Article

Panion & BF Biotech announces positive top-line results from pivotal phase 3 study of Ferric Citrate
Tuesday, 29 Mar 2016 08:45pm EDT 

Panion & BF Biotech Inc:Says its authorized partner Keryx Biopharmaceuticals announces positive top-line results from pivotal phase 3 study of Ferric Citrate(U.S name is Auryxia and named Nephoxil in Taiwan), for the Treatment of Iron Deficiency Anemia in Adults with Non-Dialysis Dependent Chronic Kidney Disease.  Full Article

Panion & BF Biotech receives penalty order
Tuesday, 22 Mar 2016 05:01am EDT 

Panion & BF Biotech Inc:Be imposed fine of T$120,000 by Department of Health, Taipei City Government, due to its violation of Act Governing Food Safety and Sanitation.  Full Article

Panion & BF Biotech receives clinic trial approval from China Food and Drug Administration for Nephoxil
Tuesday, 17 Nov 2015 03:30am EST 

Panion & BF Biotech Inc:Received clinic trial approval from China Food and Drug Administration for Nephoxil, which is a new drug for treatment of high serum phosphorus of patients with chronic kidney disease.  Full Article

Panion & BF Biotech receives new drug marketing permission for Nephoxil in Europe
Thursday, 24 Sep 2015 08:53pm EDT 

Panion & BF Biotech Inc:Received new drug marketing permission for its kidney drug Nephoxil in Europe from European Commission.  Full Article

Panion & BF Biotech announces 2014 dividend date
Thursday, 13 Aug 2015 06:11am EDT 

Panion & BF Biotech Inc:To use undistributed profit to pay cash dividends of T$0.15 per share to shareholders for 2014.To use undistributed profit to distribute stock dividend worth T$0.60 for every one share.To use additional paid-in capital to distribute stock dividend worth T$1 for every one share.Ex-dividend date Sep. 3.Last date before book closure Sep. 4 with book closure period from Sep. 5 to Sep. 9.Record date Sep. 9.  Full Article

Panion & BF Biotech announces 2014 dividend payment
Friday, 17 Apr 2015 04:51am EDT 

Panion & BF Biotech Inc:To use undistributed profit to pay cash dividends of T$0.15 per share to shareholders for 2014.To pay cash dividend of T$7,269,223 in total.To use undistributed profit to distribute stock dividend worth T$0.60 for every one share.To use additional paid-in capital to distribute stock dividend worth T$1 for every one share.To distribute stock dividend of 7,753,838 shares in total.  Full Article

Panion & BF Biotech to set up joint venture with Shangdong-based company
Monday, 23 Feb 2015 07:49pm EST 

Panion & BF Biotech Inc:To set up a joint venture, which to be engaged in development, manufacture and sale of drug Nephoxil in China Mainland, with a Shangdong-based medical company.To hold 49 pct stake and the Shangdong-based company to hold 51 pct stake in the joint venture.To authorize patented technology to the joint venture with license agreement amount of 150 million yuan.  Full Article

No consensus analysis data available.